255TiP AIPAC-003: A randomized, double-blind, placebo-controlled phase III trial testing eftilagimod alpha (soluble LAG-3) in HER2-neg/low metastatic breast cancer patients receiving paclitaxel, following an open-label dose optimization

التفاصيل البيبلوغرافية
العنوان:	255TiP AIPAC-003: A randomized, double-blind, placebo-controlled phase III trial testing eftilagimod alpha (soluble LAG-3) in HER2-neg/low metastatic breast cancer patients receiving paclitaxel, following an open-label dose optimization
المؤلفون:	Duhoux, F.P., Ibrahim, N.K., Papadamitriou, K., Canon, J-L., Morales, S., Sanchez-Rovira, P., Oliveira, M., Doger de Spéville, B., Houtsma, D., Beeker, A., Peguero, J., Marathe, O., Triebel, F.
المصدر:	In ESMO Open May 2023 8(1) Supplement 4
قاعدة البيانات:	ScienceDirect

الوصف
تدمد:	20597029
DOI:	10.1016/j.esmoop.2023.101443